ABBV-951市場：市場規模、予測、市場洞察-2032年

ABBV-951は、AbbVieが開発中のホスレボドパ/ホスカルビドパ含有治験薬です。カルビドパとレボドパのプロドラッグを持続的に皮下投与する溶液で、進行したパーキンソン病患者の運動機能変動に対する治療薬として検討されています。本剤はドパミン受容体を標的とする低分子化合物です。

CD/LDを24時間持続的に皮下投与できるように設計されています。経口CD/LDと比較して、進行性パーキンソン病患者の運動ゆらぎを改善する可能性があります。進行性パーキンソン病は、ドーパミンを産生する脳細胞の消失に起因する進行性かつ慢性の神経疾患で、主に振戦、筋硬直、動作緩慢、バランス障害を示します。

最近、AbbVie社はABBV-951（ホスカルビドパ／ホスレボドパ）の新薬承認申請（NDA）に対する審査完了報告書（CRL）を受領しました。同社は第III相試験であるM15-736試験のデータに基づいて新薬承認申請を提出していました。

今後数年間で、パーキンソン病の市場シナリオは、世界中の広範な調査と医療費の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、ABBV-951の優位性に影響を与える可能性のある機会を模索しています。

他のパーキンソン病治療薬もABBV-951と厳しい市場競争を繰り広げることが予想され、近い将来、後発の新興治療薬が上市されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるパーキンソン病治療薬のABBV-951市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるABBV-951の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 ABBV-951市場評価

• パーキンソン病におけるABBV-951市場の見通し
• 主要7ヶ国分析
  • 主要7ヶ国のパーキンソン病治療におけるABBV-951市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: ABBV-951, Clinical Trial Description, 2023
• Table 2: ABBV-951, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: ABBV-951 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: ABBV-951 Market Size in the US, in USD million (2019-2032)
• Table 7: ABBV-951 Market Size in Germany, in USD million (2019-2032)
• Table 8: ABBV-951 Market Size in France, in USD million (2019-2032)
• Table 9: ABBV-951 Market Size in Italy, in USD million (2019-2032)
• Table 10: ABBV-951 Market Size in Spain, in USD million (2019-2032)
• Table 11: ABBV-951 Market Size in the UK, in USD million (2019-2032)
• Table 12: ABBV-951 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: ABBV-951 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: ABBV-951 Market Size in the United States, USD million (2019-2032)
• Figure 3: ABBV-951 Market Size in Germany, USD million (2019-2032)
• Figure 4: ABBV-951 Market Size in France, USD million (2019-2032)
• Figure 5: ABBV-951 Market Size in Italy, USD million (2019-2032)
• Figure 6: ABBV-951 Market Size in Spain, USD million (2019-2032)
• Figure 7: ABBV-951 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: ABBV-951 Market Size in Japan, USD million (2019-2032)

"ABBV-951 Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about ABBV-951 for Parkinson's disease in the seven major markets. A detailed picture of the ABBV-951 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ABBV-951 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ABBV-951 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

ABBV-951 is an investigational drug-containing foslevodopa /foscarbidopa being developed by AbbVie. It is a solution of carbidopa and levodopa prodrugs for continuous subcutaneous delivery that is being investigated for the treatment of motor fluctuations in patients with advanced Parkinson's disease. It is a small molecule that targets dopamine receptors.

It is designed to provide 24-hour, continuous subcutaneous delivery of CD/LD. Compared to oral CD/LD, it offers the potential for improvement in motor fluctuations in patients with advanced Parkinson's disease, a progressive and chronic neurological disorder resulting from the loss of dopamine-producing brain cells, which primarily manifests with tremor, muscle rigidity, slowness of movement and difficulty with balance.

Recently, AbbVie received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ABBV-951 (foscarbidopa/foslevodopa). It had submitted NDA based on data from the M15-736 study, a Phase III trial.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ABBV-951 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on ABBV-951 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ABBV-951 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around ABBV-951.
• The report contains forecasted sales of ABBV-951 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for ABBV-951 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ABBV-951 Analytical Perspective by DelveInsight

• In-depth ABBV-951 Market Assessment

This report provides a detailed market assessment of ABBV-951 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• ABBV-951 Clinical Assessment

The report provides the clinical trials information of ABBV-951 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ABBV-951 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to ABBV-951 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ABBV-951 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of ABBV-951 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ABBV-951 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of ABBV-951?
• What is the clinical trial status of the study related to ABBV-951 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ABBV-951 development?
• What are the key designations that have been granted to ABBV-951 for Parkinson's disease?
• What is the forecasted market scenario of ABBV-951 for Parkinson's disease?
• What are the forecasted sales of ABBV-951 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to ABBV-951 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. ABBV-951 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ABBV-951 Market Assessment

• 5.1. Market Outlook of ABBV-951 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ABBV-951 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ABBV-951 in the United States for Parkinson's disease
  • 5.3.2. Market Size of ABBV-951 in Germany for Parkinson's disease
  • 5.3.3. Market Size of ABBV-951 in France for Parkinson's disease
  • 5.3.4. Market Size of ABBV-951 in Italy for Parkinson's disease
  • 5.3.5. Market Size of ABBV-951 in Spain for Parkinson's disease
  • 5.3.6. Market Size of ABBV-951 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of ABBV-951 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options